Merck & Co., Inc. (NYSE:MRK) Shares Down 1.9% – What’s Next?

Shares of Merck & Co., Inc. (NYSE:MRK) traded down 1.9% during trading on Monday . The stock traded as low as $121.04 and last traded at $121.42. 11,441,558 shares were traded during mid-day trading, a decline of 12% from the average session volume of 13,060,745 shares. The stock had previously closed at $123.82.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Guggenheim increased their price objective on Merck & Co., Inc. from $122.00 to $140.00 and gave the company a “buy” rating in a research note on Friday, February 6th. Morgan Stanley upped their price target on Merck & Co., Inc. from $100.00 to $102.00 and gave the stock an “equal weight” rating in a report on Friday, December 12th. Wells Fargo & Company lifted their price objective on Merck & Co., Inc. from $125.00 to $135.00 and gave the company an “overweight” rating in a research note on Wednesday, February 4th. Scotiabank boosted their price objective on Merck & Co., Inc. from $105.00 to $120.00 and gave the stock a “sector outperform” rating in a research report on Thursday, December 4th. Finally, Zacks Research lowered shares of Merck & Co., Inc. from a “hold” rating to a “strong sell” rating in a research note on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $125.88.

Merck & Co., Inc. Stock Performance

The firm has a 50-day simple moving average of $112.93 and a 200 day simple moving average of $97.49. The company has a market cap of $300.20 billion, a price-to-earnings ratio of 16.68, a price-to-earnings-growth ratio of 2.40 and a beta of 0.28. The company has a quick ratio of 1.30, a current ratio of 1.54 and a debt-to-equity ratio of 0.89.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The company had revenue of $16.40 billion during the quarter, compared to analysts’ expectations of $16.19 billion. During the same period last year, the firm earned $1.72 EPS. The firm’s revenue for the quarter was up 5.0% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, sell-side analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th will be issued a $0.85 dividend. The ex-dividend date of this dividend is Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a yield of 2.8%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 46.70%.

Insider Activity

In other news, CMO Chirfi Guindo sold 20,000 shares of Merck & Co., Inc. stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $121.88, for a total transaction of $2,437,600.00. Following the completion of the transaction, the chief marketing officer owned 80,615 shares of the company’s stock, valued at $9,825,356.20. The trade was a 19.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Caroline Litchfield sold 41,997 shares of the stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $119.61, for a total transaction of $5,023,261.17. Following the completion of the sale, the chief financial officer directly owned 90,192 shares in the company, valued at approximately $10,787,865.12. The trade was a 31.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 320,176 shares of company stock valued at $38,281,735 in the last 90 days. Insiders own 0.13% of the company’s stock.

Institutional Trading of Merck & Co., Inc.

Several institutional investors and hedge funds have recently modified their holdings of the business. Kingdom Financial Group LLC. purchased a new stake in Merck & Co., Inc. in the 4th quarter valued at approximately $25,000. Prosperity Bancshares Inc purchased a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at $26,000. Abound Financial LLC acquired a new stake in shares of Merck & Co., Inc. during the fourth quarter valued at $26,000. IFC & Insurance Marketing Inc. purchased a new stake in Merck & Co., Inc. during the 4th quarter worth about $31,000. Finally, High Note Wealth LLC raised its stake in Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after purchasing an additional 109 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.